| Michele Jehenson, DDS | |
|
300 Pasteur Dr, Stanford, CA 94305-2200 | |
| (650) 723-4000 | |
| Not Available |
| Full Name | Michele Jehenson |
|---|---|
| Gender | Female |
| Speciality | Oral Surgery |
| Experience | 37 Years |
| Location | 300 Pasteur Dr, Stanford, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649445826 | NPI | - | NPPES |
| ZZZ23054Z | Other | CA | MEDICARE PTAN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanford Health Care | Stanford, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stanford Health Care | 6709797491 | 2572 |
News Archive
The epilepsy drug valproate poses a higher risk for fetal death and birth defects than other commonly used epilepsy drugs, according to a study published in the August 8, 2006, issue of Neurology.
Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.
The Royal Society has called on the United Nations to introduce a ban on human reproductive cloning at its 59th General Session in October.
Researchers have devised a new plan of attack against a group of deadly childhood brain cancers collectively called diffuse midline gliomas, including diffuse intrinsic pontine glioma, thalamic glioma and spinal cord glioma.
Eli Lilly and Company has announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder.
› Verified 4 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
The epilepsy drug valproate poses a higher risk for fetal death and birth defects than other commonly used epilepsy drugs, according to a study published in the August 8, 2006, issue of Neurology.
Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.
The Royal Society has called on the United Nations to introduce a ban on human reproductive cloning at its 59th General Session in October.
Researchers have devised a new plan of attack against a group of deadly childhood brain cancers collectively called diffuse midline gliomas, including diffuse intrinsic pontine glioma, thalamic glioma and spinal cord glioma.
Eli Lilly and Company has announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder.
› Verified 4 days ago
| Entity Name | Abaci And Massey Pain Management Center A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487758074 PECOS PAC ID: 0648165043 Enrollment ID: O20040216000803 |
News Archive
The epilepsy drug valproate poses a higher risk for fetal death and birth defects than other commonly used epilepsy drugs, according to a study published in the August 8, 2006, issue of Neurology.
Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.
The Royal Society has called on the United Nations to introduce a ban on human reproductive cloning at its 59th General Session in October.
Researchers have devised a new plan of attack against a group of deadly childhood brain cancers collectively called diffuse midline gliomas, including diffuse intrinsic pontine glioma, thalamic glioma and spinal cord glioma.
Eli Lilly and Company has announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder.
› Verified 4 days ago
| Entity Name | Lpch Medical Group Div Of Lucile |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
The epilepsy drug valproate poses a higher risk for fetal death and birth defects than other commonly used epilepsy drugs, according to a study published in the August 8, 2006, issue of Neurology.
Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.
The Royal Society has called on the United Nations to introduce a ban on human reproductive cloning at its 59th General Session in October.
Researchers have devised a new plan of attack against a group of deadly childhood brain cancers collectively called diffuse midline gliomas, including diffuse intrinsic pontine glioma, thalamic glioma and spinal cord glioma.
Eli Lilly and Company has announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michele Jehenson, DDS 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 | Michele Jehenson, DDS 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 |
News Archive
The epilepsy drug valproate poses a higher risk for fetal death and birth defects than other commonly used epilepsy drugs, according to a study published in the August 8, 2006, issue of Neurology.
Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.
The Royal Society has called on the United Nations to introduce a ban on human reproductive cloning at its 59th General Session in October.
Researchers have devised a new plan of attack against a group of deadly childhood brain cancers collectively called diffuse midline gliomas, including diffuse intrinsic pontine glioma, thalamic glioma and spinal cord glioma.
Eli Lilly and Company has announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder.
› Verified 4 days ago